Epitope distance to the target cell membrane and antigen size determine the potency of T cell-mediated lysis by BiTE antibodies specific for a large melanoma surface antigen
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516
Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer
Zhang, L., Conejo-Garcia, J. R., Katsaros, D., Gimotty, P. A., Massobrio, M., Regnani, G., Makrigiannakis, A., Gray, H., Schlienger, K., Liebman, M. N., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020177 · Cited by 3,397 · cited 1×
“, for patients with colorectal cancer [3], ovarian cancer [4], and non-Hodgkin lymphoma [5].”
BackgroundTumor Regression in Cancer Patients by Very Low Doses of a T Cell–Engaging Antibody
Bargou, R., Leo, E., Zugmaier, G., Klinger, M., Goebeler, M., Knop, S., Noppeney, R., Viardot, A., Hess, G., Schuler, M., et al. (2008) · Science · doi:10.1126/science.1158545 · Cited by 1,078 · cited 2×
“Encouraging clinical results were also reported for bispecific antibody blinatumomab (MT103), which can engage T cells for redirected lysis of CD19-expressing lymphoma and leukemia cells [16].”
BackgroundResultSelf-citationBispecific T-Cell Engaging Antibodies for Cancer Therapy
Baeuerle, P. A., & Reinhardt, C. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0547 · Cited by 592 · cited 1×
“Blinatumomab belongs to the class of ‘bispecific T cell engager’ (BiTE) [18], which can transiently connect T cells and target cells via binding to CD3 and a selected surface target antigen.”
BackgroundSelf-citationRibas, A., Camacho, L. H., Lopez-Berestein, G., Pavlov, D., Bulanhagui, C. A., Millham, R., Comin-Anduix, B., Reuben, J. M., Seja, E., Parker, C. A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.109 · Cited by 591 · cited 1×
“Antibodies blocking CTLA-4 on T cells [9, 10] or adoptive T cell transfer [11–13] showed stunning tumor regression in late-stage melanoma patients, albeit at low response rates.”
BackgroundOffner, S., Hofmeister, R., Romaniuk, A., Kufer, P., & Baeuerle, P. A. (2006) · Molecular Immunology · doi:10.1016/j.molimm.2005.03.007 · Cited by 365
Self-citationHoffmann, P., Hofmeister, R., Brischwein, K., Brandl, C., Crommer, S., Bargou, R., Itin, C., Prang, N., & Baeuerle, P. A. (2005) · International Journal of Cancer · doi:10.1002/ijc.20908 · Cited by 344
Self-citationBrischwein, K., Schlereth, B., Guller, B., Steiger, C., Wolf, A., Lutterbuese, R., Offner, S., Locher, M., Urbig, T., Raum, T., et al. (2006) · Molecular Immunology · doi:10.1016/j.molimm.2005.07.034 · Cited by 256
Self-citationBrischwein, K., Parr, L., Pflanz, S., Volkland, J., Lumsden, J., Klinger, M., Locher, M., Hammond, S. A., Kiener, P., Kufer, P., et al. (2007) · Journal of Immunotherapy · doi:10.1097/cji.0b013e318156750c · Cited by 187
Self-citationLutterbuese, R., Raum, T., Kischel, R., Lutterbuese, P., Schlereth, B., Schaller, E., Mangold, S., Rau, D., Meier, P., Kiener, P. A., et al. (2009) · Journal of Immunotherapy · doi:10.1097/cji.0b013e31819b7c70 · Cited by 77 · cited 3×
“Despite the need of relatively high in vitro concentrations for redirected lysis, CEA-specific BiTE antibodies showed a very significant anti-tumor activity in two different mouse models [20].”
BackgroundSelf-citation
Cited by
Bispecific antibodies: a mechanistic review of the pipeline
Labrijn, A. F., Janmaat, M. L., Reichert, J. M., & Parren, P. W. H. I. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0028-1 · Cited by 1,303
Mechanisms for T cell receptor triggering
van der Merwe, P. A., & Dushek, O. (2011) · Nature Reviews Immunology · doi:10.1038/nri2887 · Cited by 482
Herter, S., Herting, F., Mundigl, O., Waldhauer, I., Weinzierl, T., Fauti, T., Muth, G., Ziegler-Landesberger, D., Van Puijenbroek, E., Lang, S., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-1182 · Cited by 366
Bispecific Antibodies: From Research to Clinical Application
Ma, J., Mo, Y., Tang, M., Shen, J., Qi, Y., Zhao, W., Huang, Y., Xu, Y., & Qian, C. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.626616 · Cited by 305
Li, J., Stagg, N. J., Johnston, J., Harris, M. J., Menzies, S. A., DiCara, D., Clark, V., Hristopoulos, M., Cook, R., Slaga, D., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.02.001 · Cited by 296
Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies
Tian, Z., Liu, M., Zhang, Y., & Wang, X. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01084-4 · Cited by 282
Current progress in innovative engineered antibodies
Strohl, W. R. (2018) · Protein & Cell · doi:10.1007/s13238-017-0457-8 · Cited by 279
Versatile strategy for controlling the specificity and activity of engineered T cells
Ma, J. S. Y., Kim, J. Y., Kazane, S. A., Choi, S.-H., Yun, H. Y., Kim, M. S., Rodgers, D. T., Pugh, H. M., Singer, O., Sun, S. B., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1524193113 · Cited by 273
Engelberts, P. J., Hiemstra, I. H., de Jong, B., Schuurhuis, D. H., Meesters, J., Beltran Hernandez, I., Oostindie, S. C., Neijssen, J., van den Brink, E. N., Horbach, G. J., et al. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2019.102625 · Cited by 172
Bispecific antibodies targeting mutant RAS neoantigens
Douglass, J., Hsiue, E. H.-C., Mog, B. J., Hwang, M. S., DiNapoli, S. R., Pearlman, A. H., Miller, M. S., Wright, K. M., Azurmendi, P. A., Wang, Q., et al. (2021) · Science Immunology · doi:10.1126/sciimmunol.abd5515 · Cited by 171
Lutterbuese, R., Raum, T., Kischel, R., Hoffmann, P., Mangold, S., Rattel, B., Friedrich, M., Thomas, O., Lorenczewski, G., Rau, D., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1000976107 · Cited by 166
Self-citationComputational stabilization of T cell receptors allows pairing with antibodies to form bispecifics
Froning, K., Maguire, J., Sereno, A., Huang, F., Chang, S., Weichert, K., Frommelt, A. J., Dong, J., Wu, X., Austin, H., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16231-7 · Cited by 37
Solution structure and synaptic analyses reveal determinants of bispecific T cell engager potency
Leithner, A., Staufer, O., Mitra, T., Liberta, F., Valvo, S., Kutuzov, M., Dada, H., Spaeth, J., Zhou, W., Schiele, F., et al. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2425781122 · Cited by 22
Metadata
- Authors
- Bluemel, C., Hausmann, S., Fluhr, P., Sriskandarajah, M., Stallcup, W. B., Baeuerle, P. A., & Kufer, P.
- Venue
- Cancer Immunology, Immunotherapy
- Published
- 2010-03-23
- Volume
- 59
- Issue
- 8
- Pages
- 1197-1209
- ISSN
- 0340-7004 (ISSN-L)
- 1432-0851
- OpenAlex
- W2055342376
- Cited by
- 205
- References
- 11
- FWCI
- 7.96
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.